

## CURRICULUM VITAE

Sarah Sorscher, JD, MPH  
March 2016

### CONTACT INFORMATION:

Work Address: Public Citizen  
1600 20<sup>th</sup> Street, NW  
Washington, DC 20009  
Work Telephone: 202-588-7726  
Work Fax: 202-588-7796  
Work E-mail: [ssorscher@citizen.org](mailto:ssorscher@citizen.org)

### PRESENT POSITION:

Researcher  
Health Research Group  
Public Citizen  
Washington, DC  
September 2011-present

### PREVIOUS PROFESSIONAL EXPERIENCE:

Public Health Intern  
New England Tuberculosis Consortium  
Boston, MA  
February 2010-June 2010

Board Member  
Board of Directors  
Universities Allied for Essential Medicines  
Oakland, CA  
November 2011 - present

Legal Intern  
Office of Chief Counsel  
Food and Drug Administration  
Rockville, MD  
June 2009 – August 2009

Intern  
Right to Health Project  
Egyptian Initiative for Personal Rights  
Cairo, Egypt  
November 2006 – August 2007

Consumer Health Advocate  
Urban Justice Center  
New York, NY  
September 2005 – November 2006

## **EDUCATION:**

College: Amherst College  
Amherst, MA  
2001- 2005: BA, Anthropology

Law School: Harvard Law School  
Cambridge, MA  
2007-2010: JD

Graduate Education: Harvard School of Public Health  
Cambridge, MA  
2008-2010: MPH

Clerkship: Judge Stephen Glickman  
Court of Appeals for the District of Columbia  
Washington, DC  
2010-2011

## **EDITORIAL ACTIVITIES**

Masthead Editor  
Harvard Journal of Law and Technology, 2008-2009

## **BAR MEMBERSHIP**

Washington State Bar: ID # 43396  
2011 – present

## **HONORS/AWARDS**

Harvard Law School, graduated *cum laude*, 2010

Harvard Law School Dean's Scholar, Health Law and Regulation, 2009

Amherst College, graduated *magna cum laude*, 2005

*Phi Beta Kappa*, 2005

## **BIBLIOGRAPHY:**

### **PUBLICATIONS**

1. Sorscher S. A longer monopoly for biologics?: Considering the implications of data exclusivity as a tool for innovation policy. *Harvard J Law and Tech*. 2009;23:285-308.

### **REGULATORY FILINGS AND COMMUNICATIONS**

1. Rajput R, Sorscher S, Carome MA. Petition to the FDA to not Allow Marketing of Over-the-Counter Benzocaine Products for Teething Infants. July 28, 2014. <http://www.citizen.org/hrg2209>.
2. Sorscher S, Carome MA. Public Citizen Urges FDA to Take Action for Sale of Misbranded Brain Stent Device. April 3, 2014. <http://www.citizen.org/hrg2193>.
3. Sorscher S, Carome MA. Public Citizen asks the FDA to Prohibit Traditional Compounding Pharmacies from Engaging in High Risk Sterile Compounding. March 4, 2014. <http://www.citizen.org/hrg2188>.
4. Sorscher S, Carome MA. Public Citizen asks the Food and Drug Administration (FDA) to clarify the line between pharmacy compounding and drug manufacturing. February 3, 2014. <http://www.citizen.org/hrg2180>.
5. Sorscher S, Carome MA. Letter to FDA Commissioner Margaret Hamburg criticizing agency messages endorsing compounded drugs made by outsourcing facilities. December 17, 2013. <http://www.citizen.org/hrg2175>.
6. Sorscher S, Carome MA. Public Citizen supports European policy on publication of clinical trials data. September 30, 2013. <http://www.citizen.org/hrg2163>.
7. Sorscher S, Carome MA. Letter to HHS Secretary Sebelius regarding specialty compounding. August 14, 2013. <http://www.citizen.org/hrg2148>
8. Sorscher S, Carome MA. Public Citizen comments on the draft revision of the Declaration of Helsinki. June 14, 2013. <http://www.citizen.org/documents/2137.pdf>.
9. Sorscher S, Carome MA, Wolfe SM. Letter to the FDA criticizing the decision to keep the Wingspan Stent System on the market. January 28, 2013.
10. Sorscher S, Carome MA, Wolfe SM. Comments submitted to the FDA regarding automated external cardiac compressor devices. April 8, 2013.
11. Sorscher S, Carome MA. Comments on sorbent hemoperfusion, cranial electrotherapy stimulators, and transilluminators for breast evaluation. May 6, 2013. <http://www.citizen.org/hrg2122>.
12. Sorscher S, Carome MA. Public Citizen comments on regulatory classification of automated external defibrillator (AED) devices. June 24, 2013. <http://www.citizen.org/hrg2139>.

13. Sorscher S, Carome MA, Wolfe SM. Letter to the FDA demanding explanation for dangerous delay between identifying problems and public recall of potentially contaminated products distributed by Balanced Solutions Compounding Pharmacy. April 22, 2013. <http://www.citizen.org/hrg2117>.
14. Carome MA, Sorscher S, Wolfe SM. Comments submitted to the FDA's drug shortages task force. March 14, 2013.
15. Sorscher S, Carome MA, Wolfe SM. Letter to the FDA urging re-inspection of compounding pharmacies with serious safety violations. November 29, 2012. <http://www.citizen.org/hrg2085>.
16. Levin J, Sorscher S, Wolfe SM. Public Citizen Comment on Corrective Ad Study. April 27, 2012. <http://www.citizen.org/hrg2028>.
17. Sorscher S, Carome MA, Wolfe SM. Letter to Medicare and Medicaid on Wingspan Stent System, February 14, 2012. <http://www.citizen.org/hrg1999>.
18. Almashat S, Sorscher S, Wolfe SM. Letter to FDA on IABP regulatory classification. February 13, 2013. <http://www.citizen.org/hrg2094>
19. Sorscher S, Carome MA, Wolfe SM. Public Citizen comment on external pacemaker reclassification. January 17, 2012. <http://www.citizen.org/hrg1995>.

#### **COMMUNICATIONS WITH CONGRESS**

1. Sorscher S, Carome MA, Wolfe SM. Public Citizen's comments on Senate HELP Committee draft proposal for regulatory oversight of compounding pharmacies. May 3, 2013.
2. Carome MA, Sorscher S, Wolfe, SM. Comments to the Senate Committee on Health, Education, Labor, and Pensions on the FDA's flawed proposal for oversight of compounding pharmacies. November 30, 2012. <http://www.citizen.org/hrg2086>.
3. Carome MA, Sorscher S, Wolfe, SM. Response to Senate HELP Committee's questions regarding compounding pharmacies. November 2, 2012. <http://www.citizen.org/hrg2082>.

#### **PRESENTATIONS/TESTIMONY**

1. Sorscher S. Presentation on pharmacy compounding before the Food and Drug Law Institute Enforcement, Litigation, and Compliance Conference. December 18, 2013. <http://www.citizen.org/hrg2176>.
2. Sorscher S. Public Citizen opposes reclassification of external cardiac compressor devices. September 11, 2013. <http://www.citizen.org/hrg2157>.

#### **LETTERS TO THE EDITOR**

3. Carome MA, Sorscher S. Compounding pharmacies can be regulated by FDA. The Washington Post. April 21, 2013.

#### **CONSUMER NEWSLETTER PUBLICATIONS**

1. Risks of Ospemifene For Menopause-Related Pain During Intercourse. *Worst Pills, Best Pills Newsletter*. June 2014.
2. Type 2 Diabetes: A Guide to Prevention and Treatment. *Worst Pills, Best Pills Newsletter*. May 2014.
3. NUVARING: Do Not Use. *Worst Pills, Best Pills Newsletter*. April 2014.
4. New FDA Online Portal for Reporting Problems with Dietary Supplements. *Health Letter*. April 2014.
5. FDA Requires Testing for “Antiseptic” Soap. *Health Letter*. March 2014.
6. Painkiller Patches Cause Accidental Deaths in Children. *Worst Pills, Best Pills Newsletter*. February 2014.
7. New Law on Pharmacy Compounding May Increase Risks for Consumers. *Health Letter*. February 2014.
8. Hormone Replacement Therapy: Use at the Lowest Dose for the Shortest Amount of Time. *Worst Pills, Best Pills Newsletter*. January 2014.
9. The FDA’s Proposed Partial Ban on Some Trans Fats. *Health Letter*. January 2014.
10. Choosing Between Cesarean Section and Vaginal Delivery? Consider the Physician’s Role. *Health Letter*. December 2013.
11. Zinc as a Cold Remedy: Still Waiting for Good Evidence. *Worst Pills, Best Pills Newsletter*. November 2013.
12. "Normal" Weight and Aging. *Health Letter*. November 2013.
13. Uncovering Quality Concerns in Nursing Homes. *Health Letter*. October 2013.
14. Excitement Fades for Off-Label Alzheimer’s Treatment. *Worst Pills, Best Pills Newsletter*. September 2013.
15. Normal Memory Loss and Dementia: How to Tell the Difference. *Health Letter*. September 2013.
16. Genetic Testing for Breast Cancer: Is It Right for You? *Health Letter*. August 2013.
17. Protect Others by Reporting Your Child’s Problems with Medical Products. *Health Letter*. July 2013.
18. What Dangers are Hidden in Your Weight-Loss Supplement? *Worst Pills, Best Pills Newsletter*. May 2013.
19. More on the New Stroke Prevention Drugs. *Worst Pills, Best Pills Newsletter*. May 2013.
20. LASIK Eye Surgery: Know the Risks, Not Just the Benefits. *Health Letter*. May 2013.

21. Emerging Risks with the New Stroke Prevention Drugs. *Worst Pills, Best Pills Newsletter*. April 2013.
22. Objects Left Behind After Surgery. *Health Letter*. April 2013.
23. Buying Drugs Online Presents Hidden Risks. *Health Letter*. March 2013.
24. FDA Fails to Ban Toxic Lice and Scabies Treatment Lindane. *Worst Pills, Best Pills Newsletter*. February 2013.
25. Early Testing For Alzheimer's Disease. *Health Letter*. February 2013.
26. Vitamin D and Calcium for Bone Health: Getting the Right Amount. *Worst Pills, Best Pills Newsletter*. January 2013.
27. Steroid Injections and Other Treatments for Lower Back Pain. *Worst Pills, Best Pills Newsletter*. November 2012.
28. Angioplasty Offers Little Benefit for Low-Risk Patients. *Health Letter*. November 2012.
29. Diet and Exercise: Still the Best Medicine for Losing Weight or Keeping Fit. *Worst Pills, Best Pills Newsletter*. October 2012.
30. Smoking Cessation: What Works and What Doesn't. *Worst Pills, Best Pills Newsletter*. September 2012.
31. New Advice on Treating Sinus Infections with Antibiotics. *Worst Pills, Best Pills Newsletter*. August 2012.
32. Measuring Blood Pressure in Both Arms Could Help Predict Risks. *Health Letter*. July 2012.
33. Wide Variation in Rates of Second Breast Cancer Surgery. *Health Letter*. May 2012.
34. Scientific Fraud on the Rise: Its Impact on Patients and Research. *Health Letter*. April 2012.